Hologic (NSDQ:HOLX) said its nearly $4 billion buyout of molecular diagnostics giant Gen-Probe (NSDQ:GPRO) is in the books, a day after Gen-Probe’s shareholders OK’d the $82.75-per-share deal.

The acquisition, valued at about $3.7 billion, puts Hologic in the top tier of the diagnostics space, outside of its traditional market, women’s health.

Hologic said the deal should add 20¢ per adjusted share during fiscal 2013 and should be "significantly more accretive" thereafter.

Sign up to get our free newsletters delivered straight to your inbox

News of the deal‘s closure, and strong fiscal 3rd-quarter numbers, has helped add 2.7% to HOLX shares since July 30. The stock closed at $18.75 yesterday, up from an $18.26 close July 30.

Hologic reported profits of $23.6 million, or 9¢ per share, on sales of $470.2 million during the 3 months ended June 23, for top-line growth of 4.2% but a bottom-line slide of 34.8%.

Adjusted for 1-time items, however, including $5.1 million in acquisition costs and a $1.7 million charge for the wind-down of its Adiana female sterilization line, EPS hit 35¢, just a penny shy of analysts’ expectations.

Hologic moved to ditch its Adiana permanent female sterilization system after it lost a patent infringement lawsuit to Conceptus (NSDQ:CPTS).

A jury awarded Conceptus $18.8 million and royalties of 20% in October 2011 after finding that the Adiana device infringed on 5 CPTS patents, and the court later denied Hologic’s motion to overturn the jury decision.

 Masimo drops $30M on Swedish capnography co.
Masimo (NSDQ:MASI) said it paid $30.4 million in cash for Swedish capnography maker Phasein AB, funding the acquisition entirely with existing cash and equivalents.
Read more

 CardioSolutions drums up $15M

Medical device company CardioSolutions
added $14.9 million to its coffers in an equity round, just a month after announcing an $8 million contribution from Sorin Group (BIT:SRN). In June the company won 510(k) clearance from the FDA for its Dexterity steerable heart access introducer.
Read more

 Let investors in on analysts’ calls

More companies should follow the lead of Roche (PINK:RHHBY) and allow investors to participate in quarterly earnings conference calls with analysts, writes Brad Loncar on Xconomy.com.
Read more

 Earnings Roundup

• Teleflex boosts Q2 profits 25% on flat sales
• Hospira swings to Q2 red
• GI Dynamics puts up $100k in Q2 EndoBarrier sales
• Shire sells $52M worth of Dermagraft during Q2

 Analysts’ ups and downs

• Baxter (NYSE:BAX): Fitch Ratings affirms issuer default rating at "A" and short-term IDR at "F1."
• Becton Dickinson & Co. (NYSE:BDX): JP Morgan downgrades from "neutral" to "underweight," sets $72 price target.
• Boston Scientific (NYSE:BSX): Northland Securities downgrades from "outperform" to "market perform"; TheStreet Ratings downgrades from "hold" to sell.
• Bruker Corp. (NSDQ:BRKR) : Leerink Swann downgrades from "outperform" to "market perform."
• Conceptus (NSDQ:CPTS): Piper Jaffray reduces rating from "overweight" to "neutral", raises price target from $19 to $21.
• C.R. Bard (NYSE:BCR): Jefferies & Co. downgrades from "buy" to "hold," cuts price target from $104 to $94.
• Edwards Lifesciences (NYSE:EW): Zacks reaffirms “neutral” rating and $106 price target.
• Hologic (NSDQ:HOLX): Cannacord Genuity lowers price target from $24 to $23, maintains “buy” rating.
• Integra LifeSciences (NSDQ:IART): Piper Jaffray reiterates "neutral" rating, raises price target from $40 to $41.
• LeMaitre Vascular (NSDQ:LMAT): Canaccord Genuity raises price target from $7 to $8.50.
• Palomar Medical (NSDQ:PMTI): Needham & Co. cuts price target from $20 to $11, maintains "buy" rating.
• ResMed (NYSE:RMD): Morgan Stanley reiterates "overweight" rating, raises price target from $32.95 to $33.37.
• Teleflex (NYSE:TFX): Leerink Swann maintains "market perform" rating, raises price target to $69 from $67.
• Zeltiq (NSDQ:ZLTQ): Goldman Sacks raises price target from $5.50 to $6.00, maintains “neutral” rating.